Iris International to Buy AlliedPath for Up to $6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics firm Iris International announced after the close of the market Tuesday that it has agreed to buy AlliedPath, an early-stage, high-complexity CLIA-certified laboratory, for up to $6 million.

Iris will pay $4.7 million in cash and an earn-out of up to $1.3 million subject to certain sales and earnings targets being reached during the next three years. The deal is expected to close by July 30.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.